A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma

In brief

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

Key facts

Study ID: NCT03162536
Run by: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
People needed: 190
Starts: 2017-06-26
Expected to finish: 2027-09-17
Last updated by the study team: 2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Each prospective participant must meet ALL of the following inclusion criteria in order to be eligible for this study:
Signed written informed consent granted prior to initiation of any study-specific procedures
For the dose escalation cohorts, relapsed or refractory (R/R) participants with a diagnosis of B-cell Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and Waldenstrom macroglobulinemia (WM) who have received at least two prior systemic therapies . Participants must have failed or are intolerant to standard therapies and cannot be a candidate for standard salvage regimens. Participants with low grade lymphoma must be progressing and requiring treatment
For the expansion cohorts, the following criteria must be met:
Cohort A: R/R CLL/SLL participants with at least 2 prior systemic therapies and previously treated with a covalent Bruton's tyrosine kinase inhibitor (BTKi) who must have a documented Bruton's tyrosine kinase (BTK) mutation on C481 residue
Cohort B: R/R CLL/SLL participants who have failed or were intolerant to a BTKi with documentation of the absence of BTK mutation on C481 residue. In this study, intolerance to standard therapy is defined as having experienced a grade 3 or higher adverse event that was caused by the standard therapy and resulted in treatment discontinuation
Cohort C: Richter's transformation (RT) participants who have failed at least one prior therapy
Cohort D: Follicular Lymphoma (FL) participants who have failed at least 2 prior systemic therapies and are histology grade 1, 2, or 3A
Cohort E: Mantle Cell Lymphoma (MCL) participants who have failed at least 2 prior systemic therapies
Cohort F: Marginal Zone Lymphoma (MZL) participants who have failed at least 2 prior systemic therapies
Cohort G: High-grade B-cell lymphoma participants who have failed at least 2 prior systemic therapies and have known MYC and BCL2 and/or BCL6 translocations
Cohort H: WM participants who have failed at least 2 prior systemic therapies
Cohort I (Food Effect): relapsed or refractory participants with a diagnosis of B-cell NHL, CLL/SLL or WM who have received at least 2 prior systemic therapies, or 1 prior therapy for RT participants. Participants must have failed or are intolerant to standard therapies and cannot be a candidate for standard salvage regimens. Participants with low grade lymphoma must be progressing and requiring treatment.
Disease status requirement:
For CLL participanst symptomatic disease that mandates treatment (Hallek et al. 2018)
For B-cell NHL participants, measurable disease by imaging scan
For WM, serum immunoglobulin M (IgM) with a minimum IgM level of ≥ 2 times the upper limit of normal (ULN)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Good organ function
Creatinine clearance of ≥ 60 mL/min as estimated by the Cockcroft-Gault equation or by 24-hour urine collection
Total bilirubin ≤ 1.5 x institutional ULN (total bilirubin of ≤ 3 x institutional ULN in participants with documented Gilbert's syndrome)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × institutional ULN
Platelet count ≥ 50,000/µL
Absolute neutrophil count (ANC) ≥ 1000/µL
Hemoglobin (Hgb) ≥ 8.0 g/dL, stable for ≥ 1 week.

You may not qualify if…

Potential participants who meet ANY of the following exclusion criteria are not eligible for enrollment into this study:
Had immunotherapy, radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within 5 half-lives or four weeks (whichever is shorter) prior to treatment initiation, or oral therapy within 5 half-lives or one week (whichever is shorter) prior to treatment initiation
Transformation of follicular lymphoma (FL) to a more aggressive subtype of lymphoma or grade 3b FL
Participants currently being treated with the following drugs:
CYP2C8 substrates with a narrow therapeutic index (such as paclitaxel)
P-gp substrates with a narrow therapeutic index (such as digoxin)
CYP3A strong inducers (such as rifampin) Note: A washout period of at least 5 times the half-life after the last dose of any of the above treatments is required for a participant to be eligible for study enrollment
Active central nervous system (CNS) involvement
Pregnant or breast-feeding women
Has significant, ongoing co-morbid conditions which would preclude safe delivery of the study drug
Uncontrolled illness including but not limited to ongoing or active infection, symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or IV heart failure), unstable angina pectoris, cardiac arrhythmia, cardiac infarction in the past six months, and psychiatric illness that would limit compliance with study requirements
QT corrected (QTc) prolongation (defined as a QTc > 450 msecs) or other significant electrocardiogram (ECG) abnormalities including 2nd degree atrioventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min).
Active Hepatitis B or Hepatitis C infection.
Other medical or psychiatric illness or organ dysfunction which, in the opinion of the Investigator, would either compromise the participant's safety or interfere with the evaluation of the safety of the study agent
History of prior cancer within < 1 year, except for basal cell or squamous cell carcinoma of the skin, cervical cancer in situ or other in situ carcinomas

Where it is running

Mayo Clinic Hospital ( Site 0140) — Scottsdale, Arizona, United States
UCLA Hematology & Oncology ( Site 0017) — Los Angeles, California, United States
Colorado Blood Cancer Institute ( Site 0225) — Denver, Colorado, United States
University of Michigan ( Site 0018) — Ann Arbor, Michigan, United States
Mayo Clinic - Rochester ( Site 0138) — Rochester, Minnesota, United States
Duke Cancer Center ( Site 0067) — Durham, North Carolina, United States
The Ohio State University Wexner Medical Center ( Site 0056) — Columbus, Ohio, United States
Tennessee Oncology, PLLC ( Site 0020) — Nashville, Tennessee, United States
UT Southwestern Medical Center ( Site 0116) — Dallas, Texas, United States
University of Utah, Huntsman Cancer Institute ( Site 0122) — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.